Abacavir Increases Purinergic P2X7 Receptor Activation by ATP: Does a Pro-inflammatory Synergism Underlie Its Cardiovascular Toxicity?
Open Access
- 31 March 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Abstract
The cardiovascular toxicity of Abacavir is related to its purinergic structure. Purinergic P2X7-receptors (P2X7R), characterized by activation by high concentrations of ATP and with high plasticity, seem implicated. We appraise the nature of the interplay between Abacavir and P2X7R in generating vascular inflammation. The effects of Abacavir on leukocyte-endothelium interactions were compared with those of its metabolite carbovir triphosphate (CBV-TP) or ATP in the presence of apyrase (ATP-ase) or A804598 (P2X7R-antagonist). CBV-TP and ATP levels were evaluated by HPLC, while binding of Abacavir, CBV-TP and ATP to P2X7R was assessed by radioligand and docking studies. Hypersensitivity studies explored a potential allosteric action of Abacavir. Clinical concentrations of Abacavir (20 µmol/L) induced leukocyte-endothelial cell interactions by specifically activating P2X7R, but the drug did not show affinity for the P2X7R ATP-binding site (site 1). CBV-TP levels were undetectable in Abacavir-treated cells, while those of ATP were unaltered. The effects of Abacavir were Apyrase-dependent, implying dependence on endogenous ATP. Exogenous ATP induced a profile of proinflammatory actions similar to Abacavir, but was not entirely P2X7R-dependent. Docking calculations suggested ATP-binding to sites 1 and 2, and Abacavir-binding only to allosteric site 2. A combination of concentrations of Abacavir (1 µmol/L) and ATP (0.1 µmol/L) that had no effect when administered separately induced leukocyte-endothelium interactions mediated by P2X7R and involving Connexin43 channels. Therefore, Abacavir acts as a positive allosteric modulator of P2X7R, turning low concentrations of endogenous ATP themselves incapable of stimulating P2X7R into a functional proinflammatory agonist of the receptor.Keywords
Funding Information
- Ministerio de Economía, Industria y Competitividad, Gobierno de España (CTQ2017-88535-R RT2018-94436-B-I00 SAF2015-67678-R)
- Ministerio de Sanidad, Consumo y Bienestar (CB06/04/0071)
- Conselleria de Cultura, Educación y Ciencia, Generalitat Valenciana (PROMETEOII/2014/035 PROMETEO2018/141)
- Gilead Sciences (Unrestricted Grant)
This publication has 64 references indexed in Scilit:
- Detecting adenosine triphosphate in the pericellular spaceInterface Focus, 2013
- Molecular mechanism of ATP binding and ion channel activation in P2X receptorsNature, 2012
- Activation and Regulation of Purinergic P2X Receptor ChannelsPharmacological Reviews, 2011
- Clemastine Potentiates the Human P2X7 Receptor by Sensitizing It to Lower ATP ConcentrationsJournal of Biological Chemistry, 2011
- Steady-State Pharmacokinetics of Abacavir in Plasma and Intracellular Carbovir Triphosphate following Administration of Abacavir at 600 Milligrams Once Daily and 300 Milligrams Twice Daily in Human Immunodeficiency Virus-Infected SubjectsAntimicrobial Agents and Chemotherapy, 2009
- A LC-MS/MS Method for the Analysis of Intracellular Nucleoside Triphosphate LevelsPharmaceutical Research, 2009
- Negative and positive allosteric modulators of the P2X 7 receptorBritish Journal of Pharmacology, 2008
- Agonist potency at P2X7 receptors is modulated by structurally diverse lipidsBritish Journal of Pharmacology, 2007
- P2X receptor characterization and IL‐1/IL‐1Ra release from human endothelial cellsBritish Journal of Pharmacology, 2007
- Pannexin 1 in erythrocytes: Function without a gapProceedings of the National Academy of Sciences, 2006